GRML and HUBC: Comparing Two Speculative Micro-Cap Stocks
Key Takeaways
- Two very different risk profiles: GRML is a dual-track natural resources and biotech company, while HUBC is an Israel-based cybersecurity firm diversifying into critical minerals and health assets.
- Both are speculative micro-caps with limited revenue visibility, negative earnings, and thin trading floats that amplify volatility.
- Corporate restructuring is a shared theme: GRML recently rebranded from Klotho Neurosciences, while HUBC has executed multiple reverse stock splits and asset sales.
- Relative performance has diverged sharply, with GRML trading well below its 52-week high and HUBC undergoing extreme share-count adjustments tied to Nasdaq listing pressures.
- Market sentiment remains cautious on both names, driven by balance-sheet concerns, ongoing losses, and frequent capital-structure changes.
Introduction
When looking at small- and micro-cap names, the key questions often come down to whether a recovery catalyst exists and whether the capital structure can hold up long enough to see it through. This comparison focuses on GRML (Greenland Mines Ltd.) and HUBC (HUB Cyber Security Ltd.), two Nasdaq-listed companies at the more speculative end of the spectrum. Their performance and positioning tend to attract traders who accept higher volatility, given the liquidity, dilution, and execution risks involved. The sections that follow review their business models, recent momentum, and risk factors to clarify how the two stack up.
A Closer Look at GRML
GRML, Greenland Mines Ltd., runs two segments: natural resources and cell and gene therapy. The resources side targets palladium, gold, and platinum, with projects including Skaergaard in Southeast Greenland and the Sarartoq Nd-Pr rare-earth project in Southwest Greenland. The therapeutics side is advancing KLTO-202 for ALS and KLTO-101 for Alzheimer’s. The company changed its name from Klotho Neurosciences in early 2026 and is based in Charlotte, North Carolina. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Price action has stayed volatile. The shares sit at a single-digit level, well under the 52-week high, with a broad trading range over the past year. A 1-for-50 reverse split occurred recently as part of efforts to address listing thresholds. As a pre-revenue business with negative trailing net income, GRML’s profile reflects its restructuring path, exploration assets, and a modest float that can drive sharp moves. Its high beta highlights sensitivity to news and speculative trading.
A Closer Look at HUBC
HUBC, HUB Cyber Security Ltd., delivers cybersecurity solutions across Israel, the Americas, Asia-Pacific, and Europe, with a focus on confidential computing and secured data fabric. Founded in 1984 and headquartered in Or Yehuda, Israel, it reports modest trailing revenue alongside substantial net losses. Recent moves include expansion into the Tivani critical-minerals project and a zero-cash acquisition of convertible notes linked to women’s health.
Recent trading reflects heavy capital-structure activity. HUBC has completed multiple reverse splits, including a 1-for-20 and a follow-on split, along with asset sales such as the QPoint Group. After regaining Nasdaq compliance over the summer, it received a new notification on the market value of listed securities. These developments, plus a leadership change and sharply reduced share count, have added downward pressure and kept short interest elevated.
Head-to-Head Comparison
The main difference shows up in their business models. GRML functions as a pre-revenue development company split between Greenland exploration and early-stage gene therapy, so its valuation rests almost entirely on future milestones. HUBC, on the other hand, maintains an operating revenue base in cybersecurity while carrying heavy losses and pursuing an evolving strategy that now includes critical minerals and health-related notes.
Growth drivers also differ. GRML’s potential centers on exploration results and clinical progress, both long-term and uncertain. HUBC’s narrative revolves around restructuring—asset sales, reverse splits, and board changes—rather than organic expansion. Risk factors follow the same split: GRML faces typical execution and funding risks for resource and biotech micro-caps, while HUBC contends with listing-compliance, dilution, and solvency issues tied to repeated capital changes. Sector exposure varies as well, with GRML offering commodity and healthcare angles and HUBC combining technology with a shift into hard assets. Momentum has been soft for both, with each trading near the lower end of its range and limited institutional ownership.
Tickeron AI Verdict
Based on observable factors, Tickeron’s AI would likely view both names cautiously but with a slight relative preference for GRML. Its cleaner balance sheet, modest debt, and comparatively straightforward dual business model suggest marginally better trend consistency than HUBC, which has been shaped by repeated reverse splits, listing notices, and sharp price declines. The view remains probabilistic: neither stock currently shows the stable momentum or confirmed catalysts that AI-driven strategies typically favor, so close attention to capital structures is warranted.
AI Tools in My Research Process
One resource I turn to regularly is Tickeron’s AI Trading Bots. The platform hosts hundreds of bots, each with its own strategy, timeframe, and performance record across thousands of tickers. I find the curated Trending AI Robots section especially useful because it surfaces only the strongest strategies that align with current market conditions, helping filter the options down to those with consistent recent results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
HUBC's RSI Indicator leaves overbought zone
The 10-day RSI Indicator for HUBC moved out of overbought territory on September 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 instances where the indicator moved out of the overbought zone. In 8 of the 8 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HUBC as a result. In 48 of 49 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
HUBC moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HUBC crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUBC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
HUBC broke above its upper Bollinger Band on September 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for HUBC just turned positive on October 08, 2026. Looking at past instances where HUBC's MACD turned positive, the stock continued to rise in 18 of 25 cases over the following month. The odds of a continued upward trend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.045) is normal, around the industry mean (17.861). P/E Ratio (0.000) is within average values for comparable stocks, (159.605). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (104.490).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. HUBC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ComputerCommunications
Advertisement